Skip survey header

Novo Nordisk Obesity/MASH Product Theater Evaluation-NPACE, December 8, 2026

1. I am a (please select one):
2. My specialty is (please select one):
3. Please indicate your level of agreement with the following statements:
The speaker was knowledgeable about the content. *This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
4. Please indicate your level of agreement with the following statements:
The speaker was engaging and delivered the presentation clearly and effectively. *This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
5. Please indicate your level of agreement with the following statements:
The information presented on the slides was clear and easy to understand. *This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
6. As a result of this program, I intend to:
Consider this medication as a treatment option for appropriate patients with obesity or MASH with fibrosis, according to the approved indications. *This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
7. As a result of this program, I intend to:
Initiate this treatment in appropriate patients with obesity or MASH with fibrosis, according to the approved indications. *This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
8. As a result of this program, I am better able to:
Describe the relationship between obesity, metabolic dysfunction, and potential metabolic consequences, including MASH with liver fibrosis. *This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
9. As a result of this program, I am better able to:
Identify appropriate patients for fibrosis risk assessment and apply guideline-recommended noninvasive testing (eg, FIB-4 and secondary assessment) to guide next steps. *This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
10. As a result of this program, I am better able to:
Incorporate this product into a management plan for appropriate patients with obesity or MASH with liver fibrosis that includes lifestyle intervention, appropriate dose escalation, AE monitoring, and follow-up. *This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
11. Overall:
My interest in learning about this topic and/or other topics related to it has increased as a result of attending this program.
*This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
12. Overall:
I will apply and incorporate what I learned from this program into my own practice.
*This question is required.
 12Neutral (3)45 Not applicable
Strongly DisagreeStrongly Agree
13. I am interested in receiving educational resources about MASH and use of this product for appropriate patients with MASH. *This question is required.